Lab21 secures European and USA patents for HCV drug resistance genotyping

18-May-2012 - United Kingdom

Lab21 Limited has secured new patents in Europe and the USA relating to hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing.  

The patents cover technology allowing the genotypic identification of drug resistant mutations in the four major global genotypes of HCV. The new patents represent successful extensions of the original European approval, granted in 2009. The US patent is the first successful patent Lab21 has secured in North America to protect its growing business.

Dr Berwyn Clarke, CSO at Lab21 commented: ‘Lab21 has extensive experience in the area of antiretroviral drug resistance from many years of working in HIV.  With the number of new HCV therapeutics in development and the changeable nature of the virus, we expect routine resistance analysis for HCV patients to be introduced into clinical guidelines in the near future.  Our IP in this area will be of great importance to the clinical management of these patients and will enable easy drug resistance monitoring during clinical trials.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance